開立醫療(300633.SZ):醫用內窺鏡圖像處理裝置取得醫療器械註冊證
格隆匯7月18日丨開立醫療(300633.SZ)公佈,公司的醫用內窺鏡圖像處理裝置已獲廣東省藥品監督管理局批准,於近日取得中華人民共和國醫療器械註冊證,證書批准日期為:2022年07月12日,有效期至:2027年07月11日,註冊證編號:粵械注準20222060888。
臨牀用途:配合公司生產的醫用電子內窺鏡使用,供電子內窺鏡在臨牀上的圖像處理用,併為電子內窺鏡提供照明和電源。
公司推出的X-2200系列內窺鏡圖像處理裝置,是公司首款集光源和處理器為一體的內窺鏡設備,致力於推進基礎醫療系統建設。同時,X-2200系列產品搭載了開立自主研發的光電覆合染色成像技術(VIST)和聚譜成像技術(SFI),讓高端技術下沉到基層市場,提高早癌的診斷率,讓科技惠及更廣大的羣體。X2200系列產品助力國家分級診療制度的落地,強化基層醫療的服務能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.